

CURRICULUM VITAE

Alice Lin-Tsing Yu, M.D., Ph.D.

Academic Appointments:

- 2003-present Distinguished Research Fellow and Associate Director, Genomics Research Center, Academia Sinica
- 2006-present Professor (joint appointment), Hsin Chu Biomedical Center Oncology program, National Taiwan University
- 2004-present Professor of Pediatric (joint appointment), Department of Medicine, National Taiwan University
- 2001-2003 Professor and Chief, Division of Pediatric Hematology/Oncology, University of California in San Diego
- 1994-2003 Professor, Department of Pediatrics, University of California in San Diego
- 1980-2003 Director, Pediatric Hematology/Oncology Research Program, University of California in San Diego
- 1984-1994 Associate Professor, Department of Pediatrics, University of California, San Diego
- 1977-1984 Assistant Professor, Department of Pediatrics, University of California, San Diego

Education:

College/Professional School: National Taiwan University, M.D., 1968

Graduate School: Yale University, M.S., 1969

University of Chicago, Ph.D.(Microbiology/Immunology), 1973

Post-Graduate Training and Fellowship:

Internship & Residency: Department of Pediatrics, University of Chicago, 1973-1974

Boston University, School of Medicine, 1976-1977

Fellowship: Fellow in Immunology, Children's Hospital Medical Center,

Harvard School of Medicine, 1974-1976

Certified:

1980 American Board of Pediatrics

1980 Pediatric Hematology/Oncology Subspecialty Board

1977 Physician and surgeon by the Board of Medical Quality Assurance, State of California

1975 Physician by the Board of Registration in Medicine, Commonwealth of Massachusetts

1968 Physician by the American Educational Council for Foreign Medical Graduates

Government Appointments and Scientific Advisory Committees:

2007-present Committee member for evaluating 2008 Key Government Science and Technology Programs

2006-2008 Member of the Investment Review Committee of the National Development Fund, Executive Yuan, Taiwan

2006-present Advisory Committee Member of The Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, Taiwan

2005-present Member of BioTaiwan Committee (BTC), Executive Yuan, Taiwan

2005-present Member of Life Science Promotion & Recruitment Committee, Academia Sinica, Taiwan

2005-present Member of BioTaiwan Committee, the Executive Yuan, Taiwan

2005-present Member of Advisory Board of ICH in Taiwan (the International Conference on Harmonisation of Technical Requirements of Registration of Pharmaceuticals for Human Use), Taiwan

2005-present Member of Academic Ethics Committee, Academia Sinica, Taiwan

2005-present Member of Planning Committee for Taiwan International Graduate Program, Academia Sinica, Taiwan

2004-2006 Member of Institutional Review Board for Human Subject Research, Academia Sinica, Taiwan

2004-present Consulting Expert of National Science and Technology Program for Nanoscience and Nanotechnology, Taiwan

2004-2006 Member of Scientific Advisory Committee for Development Center for Biotechnology, DCB, Taiwan

2001-2005 NCI Cancer Research Manpower Review Committee

2001-2002 Chair, Immunotherapy Subcommittee, Children's Oncology Group

2001-present Steering Committee for Neuroblastoma, Neuroblastoma Biology Committee, and ALL Biology Committee for Children's Oncology Group

2001-2003 Board of Trustee, Leukemia and Lymphoma Society, San Diego Chapter

1997-2000 Chair, Relapse ALL Biology Committee, Pediatric Oncology Group

1985-2000 Member of various committees in the Pediatric Oncology Group: Lymphoid Relapse Core Committee, Neuroblastoma Core Committee, Biological Response Modifier Committee, T-Cell Disease Committee

1998-2000 Transition Team for Pediatric Oncology Group/ Children Cancer Group: Biopathology Translational Research Committee, ALL Core Committee, Neuroblastoma Core Committee

1998-1999 NCI Special review committee for program project: "Biology and therapy of high risk neuroblastoma"

1996-2004 Reviewer for the Foundation for Pediatric Oncology Research at Groningen

1995- present Member of NIH Reviewers Reserve

- 1999 Reviewer for Children's Hospital Foundation, Winnipeg, Manitoba, Canada: "N-myc-dependent Gneomic instability in primary neuroblastoma"
- 1997 NCI Special Emphasis Panel for "Phase I Trials of Anti-cancer Agents"
- 1996 NCI Special review committee for "Investigator grants for clinical cancer therapy research"
- 1996 NIH Ad Hoc Committee for "General Clinical Research Center Grant"
- 1996-1997 Reviewer for the Foundation for Pediatric Oncology Research at Groningen
- 1991-1995 Member of Clinical Cancer Investigation Review Committee (CCIRC) at the National Institute of Health: review grant applications and conduct site visits for multicenter cooperative groups engaged in cancer investigation and treatment: SWOG, ECOG, CALGB, CCG, NSABP, ROTG, EORTC and Intergroup Rhabdomyosarcoma Study Group, etc.
- 1994 NIH Ad Hoc Committee for program project : "Gene Therapy of Cancer"
- 1994 NCI Ad Hoc Committee for "Small grants for therapeutic clinical trials"
- 1987 NIH Ad Hoc Technical Review Group for "Small Business Innovation Research Program"
- 1984&1986 Reviewer for the Medical Research Council of Canada

Chair of the following National Clinical Trials:

- 2002-2006 COG ADVL0222: A Phase II Study of Campath-1H in Children with Acute Lymphoblastic Leukemia in Second Relapse
- 1998-present: COG ANBL0032: Phase III Randomized Study of Chimeric anti-GD2 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue, a Children's Oncology Group study.
- 08/94-06/96 POG #9347: "Human-mouse chimeric anti-GD2 monoclonal antibody in the treatment of recurrent neuroblastoma"
- 6/94-8/96 POG #9377: "A phase I study of N901-bR for patients with CD56(+) malignancies"
- 09/90-09/93 POG #9074: "A phase I trial of XomaZyme-H65 in children with T-cell acute lymphoblastic leukemia/lymphoma"
- 08/88-06/94 POG #8862: "Treatment of first marrow relapse and/or extramedullary relapse of childhood acute T-lymphoblastic leukemia/lymphoma with combination chemotherapy including 2'-deoxycoformycin"

IND (Investigational Drug) filed and approved for the following therapeutic agents:

- 1998 Mab 1A7 and QS-21 for active immunotherapy of neuroblastoma
- 1995 PN401 for the treatment of newly identified syndrome associated with pyrimidine nucleotide depletion
- 1994 Ribose for the treatment of newly identified syndrome associated with pyrimidine nucleotide depletion

- 1992 Uridine and thymidine for the treatment of newly identified syndrome associated with pyrimidine nucleotide depletion
- 1990 Mab ch14.18, a human-mouse chimeric monoclonal anti-GD2 antibody for passive immunotherapy of neuroblastoma
- 1989 Mab 14G2a, a murine monoclonal anti-GD2 antibody for passive immunotherapy of neuroblastoma
- 1980 Deoxycoformycin for the treatment of refractory T-acute lymphoblastic leukemia and chronic lymphocytic leukemia

Patent

1. Alice Yu, You-Chin Lin, Ruey-Jen Lin, “METHODS FOR DELINEATING CLINICAL RISK GROUPS IN NEUROBLASTOMA BY MIRCORNA SIGNATURE AND EXPRESSION OF DICER AND DROSHA”, US Provisional Application No. 61/137,653 (2008)
2. Alice Yu, Han-Chung Wu, Chin-Tarn Lin, De-Wei Lee, Chien-Hsin Lee, “USE OF L-PEPTIDE IN CANCER DIAGNOSIS AND THERAPY”, US Provisional Application No. 61/109,306 (2008)
3. Alice Yu, Wen-Wei Chang, Chien Hsin Lee, John Yu, Chi-Huey Wong, “COMPOSITIONS AND METHODS RELATED TO THE EXPRESSION OF GLOBO H AND SSEA3 IN BREAT CANCER STEM CELLS”, US Provisional Application No. 61/061,968 (2008)
4. Alice Yu, Chi-Huey Wong, David Ho, Yaoxing Huang, Ming-Wei Chen, Rachel Cheng, “FLU VACCINES AND METHODS OF USE THEREOF”, US Patent Application No. 12/011,032 (2008), PCT Patent Application No. PCT/US2008/000919 (2008), Taiwan Patent Application No. 97102598 (2008)
5. Alice Yu, Chi-Huey Wong, Ya-Jen Chang, “ALPHA-GALACTOSYL CERAMIDE ANALOGS AND THEIR USE AS IMMUNOTHERAPIES”, US Patent Application No. 12/082,751 (2008), PCT Patent Application No. PCT/US2008/060275 (2008), Taiwan Patent Application No. 97113475 (2008)
6. Alice Yu, Chi-Huey Wong, Ya-Jen Chang, Kun-Hsien Lin, Jung-Tung Hung, “ALPHA-GALACTOSYL CERAMIDE ANALOGS AND THEIR USE AS IMMUNOTHERAPIES”, US Patent Application No. 12/218,082 (2008)
7. Alice Yu, Chi-Huey Wong, Jia-Tsrong Jan, Edmond Cheng, “ANTI-VIRAL EFFECTS OF AN EXTRACT OF GANODERMA LUCIDUM”, US Patent Application No. 11/859,729 (2007)
8. Alice Yu, John Yu, Kuo-I Lin, Wen-Bin Yang, Chi-Huey Wong, “FUNGAL IMMUNOSTIMULATORY COMPOSITIONS”, US Patent Application No. 11/549,215 (2006), Taiwan Patent Application No. 95137640 (2006)
9. Alice Yu, Chi-Huey Wong, Hsien-Yeh Hsu, Kuo-Feng Hus, Chun-Hung Lin, Jason Hsu, Shui-Tein Chen, Kuo-I Lin, Wen-Bin Yang, John Yu, “METHODS AND COMPOSITIONS ASSOCIATED WITH ADMINISTRATION OF AN EXTRACT OF GANODERMA LUCIDUM”, Japan Patent Application No. 2007536927 (2007), Europe Patent Application No. 2005810080 (2007), Taiwan Patent Application No.: 95131055 (2006)

10. Alice Yu, Thai-Yen Ling, John Yu, "PULMONARY STEM CELLS, MODEL FOR VARIOUS VIRUS INFECTIONS, RELATED METHODS AND KITS OF PARTS", Australia Patent Application No. 2006304390 (2008), Europe Patent Application No. 2006826023 (2008), US Patent Application No. 11/252,458 (2005), Taiwan Patent Application No. 95/138019 (2005)

Honors

- 04/17/01 Honored at the San Diego Padres Stadium as Community Health Heros
- 02/03/01 Recipient of the Year 2000 "Key to Life" Award from the Leukemia & Lymphoma Society
- 08/22/00 Honored at the S.D. Padres Stadium for launching a new vaccine study for children with neuroblastoma
- 03/2000 Health Hero of year 2000, awarded by the Epilepsy Society Doctor of the year, Honorable Mention, UCSD Medical Center
- 1997 Biotech All-Stars, San Diego Padre, Qualcome Stadium

Awards & Grants:

- 2006-2008 A bivalent influenza vaccine against avian and human influenza A virus with a novel glycolipid adjuvant, grant from CDC
- 2006-2008 Radiolabeled -L-peptide for Imaging of Nasopharyngeal Carcinoma, grant from NSC
- 2004-2006 Principle Investigator, Effects of campath-1H on Leukemia and normal leukocytes, grant from Berlex
- 2003-2007 Principle Investigator, Laboratory monitoring of ADCC and NK receptors and functions in high risk neuroblastoma, FDA grant
- 2003-2008 Principle Investigator, Immune monitoring of a National phase III trial of Chimeric anti-GD2 in High Risk Neuroblastoma, COG/National Cancer Institute grant.
- 2001-2003 Principle Investigator, MTAP-targeted therapy for ALL with L-alanosine, Leukemia and Lymphoma Society Translational Research Award.
- 1997-present Cindy Matters Fund for pediatric cancer research award, S.D. Padre Foundation March 2000 Health Hero of year 2000, awarded by the Epilepsy Society
- 2000-2004 Principal Investigator, Laboratory studies for the National "Phase III Randomized Study of Chimeric anti-GD2 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue," grant from Immunex Corp.
- 1998-2001 Principal Investigator, Pilot Clinical Trial of Anti-Id Vaccine for Neuroblastoma, NIH grant
- 1998-2001 Principal Investigator, MTAP-targeted therapy for T-ALL with L-alanosine, Leukemia Society of America Translational Research Award.
- 1996-2000 Co-investigator, Pediatric Oncology Group, NIH grant

- 1996-2000 Principal Investigator, Thioredoxin in neuroblastoma: clinical significance and therapeutic implications, UCSD Cancer Center Director's Research Award.
- 1998-1999 Principal Investigator, G1 cell cycle regulation in neuroblastoma. Stern Foundation Award.
- 1996-1999 Co-Investigator, L-alanosine therapy of MTAP-deficient cancer, American Cancer Society
- 1996-1998 Principal Investigator, Exploitation of frequent p16 deletion in T-ALL therapy, NIH grant
- 1996-1998 Co-investigator, Studies on the Bas/MAP Kinase Pathway in Leukemia, Leukemia Society of America
- 1995-1997 Principal Investigator, Phase I study of N901-bR in children with CD56 (+) cancer, FDA grant Principal Investigator, Phase II trial of ch14.18 + GM-CSF in neuroblastoma, FDA grant
- 1993-1996 Principal Investigator, Combined use of ch14.18 + GM-CSF in neuroblastoma, Immunex Research and Development Corporation Principal Investigator, Novel initiative grant for pilot study of anti-GD2 in neuroblastoma, Pediatric Oncology Group, NCI grant
- 1991-1995 Co-investigator, Pediatric Oncology Grant, NCI grant
- 1988-1992 Principal Investigator, Clinical Trial of an anti-GD2 mab in neuroblastoma, FDA
- 1988-1992 Co-Investigator, Pediatric Oncology Grant, NIH grant
- 1985-1988 Principal Investigator, Clinical utility of a neuroblastoma monoclonal antibody, NIH grant Co-Investigator, Pediatric Oncology Grant, NIH grant
- 1984-1985 Principal Investigator, Exploration of novel agents for childhood AML, Pons AML Research Fund
- 1980-1983 Principal Investigator, Treatment of T-cell leukemia by inhibition of adenosine deaminase, NIH grant

Membership for Professional Societies:

International Society for Stem Cell Research
 American Society of Clinical Oncology
 American Association for Cancer Research
 American Society of Hematology
 Pediatric Oncology Group, Childrens Oncology Group
 Fellow, American Academy of Pediatrics
 Society for Pediatric Research
 Western Society for Pediatric Research

Editorial Activities:

Reviewer for the following journals:

Blood	Proceedings of the National Academy of Science
Cancer Research	American Association of Cancer Research
Journal of Clinical Oncology	Journal of Clinical Investigations
Leukemia	Journal of the National Cancer Institute
Clinical Cancer Research	Experimental Cell Research
Biochemical Pharmacology	Cancer Chemotherapy and Pharmacology
Cancer Investigation	Current Therapeutic Research
Prenatal Diagnosis, etc.	Journal of Pediatric Hematology/oncology

Member of the editorial board for the Journal of the Formosan Medical Association.

University Service:

2007-present	Consulting Expert for National Clinical Research Center of Excellence, National Taiwan University Hospital, Taiwan
2006- present	Member of Outstanding Research Promotion Advisory Committee, National Taiwan University
1999-2003	Conflict of Interest Management Subcommittee, Independent Review Committee on Conflict of Interest
1997-2003	Review and Appraisal Committee, Dept. of Pediatrics
1990-2003	Ad Hoc Academic Review Committee
1995-2003	Cancer Committee
1992-2003	Moore's UCSD Cancer Center Protocol Review & Monitoring Committee
1990-2000	GCRC advisory Committee
1996-1998	Pediatric Information System Committee
1987-1994	Pharmacy and Therapeutics Committee
1984-1987	Transfusion and Phoresis Committee
1985-2003	Faculty Mentor Program

BIBLIOGRAPHY

Alice L. Yu, M.D., Ph.D.

ARTICLES

1. Yu AL, Cohen EP*: Studies on the effect of specific antisera on the metabolism of cellular antigens. I. Isolation of thymus leukemia antigens. J Immunol 112:1285-1295, 1974.
2. Yu AL, Cohen EP*: Studies on the effect of specific antisera on the metabolism of cellular antigens. II. The synthesis and degradation of TL antigens of mouse cells in the presence of TL antiserum. J Immunol 112:1296-1307, 1974.
3. Yu AL, Liang W, Cohen EP*: Detection of a TL(+) murine leukemia cell line that resists the cytotoxic effects of guinea pig complement and specific antiserum. J Nat Cancer Inst 55:299-307, 1975.
4. Yu AL, Watts HG, Jaffe N, Parkman R*: Concomittant presence of tumor-specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma. NEJM 297:121-127, 1977.
5. Yu AL*, Kung FH, Bakay B, Nyhan WL: *In vitro* and *in vivo* effects of deoxycoformycin in human T-cell leukemia. Adv Exp Med Biol 122B:373-379, 1980.
6. Yu AL*, Bakay B, Kung FH, Nyhan WL: The effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia. Cancer Res 41:2677-2682, 1981.
7. Yu AL, Royston I, Leung K, Kung F, Hartman G, Lightsey A, Vangrov J, Sobol R*: Utility of monoclonal antibodies in the immunologic phenotyping of acute lymphoblastic leukemia. Hybridoma 1: 91-98, 1982.
8. Kamatani N, Yu AL, Carson DA*: Deficiency of methylthioadenosine phosphorylase in human leukemic cells *in vivo*. Blood 60:1387-1391, 1982.
9. Matsumoto S, Yu AL*, Bleeker L, Bakay B, Kung FH, Nyhan W: Biochemical correlates of the differential sensitivity of subtypes of human leukemia to deoxyadenosine and deoxycoformycin. Blood 60:1096-1102, 1982.
10. Matsumoto SS, Yu J, Yu AL*: Inhibition of RNA synthesis by deoxyadenosine plus deoxycoformycin in resting lymphocytes. J Immunol 131:2762-2766, 1983.
11. Carson DA*, Wasson DB, Taetl R, Yu AL: Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62:737-743, 1983.
12. Yu AL*, Matsumoto S, Bleeker L, Alvarez A, Bakay B, Nyhan WL, Kung F: Biochemical basis of the differential effects of deoxycoformycin on human leukemias. Adv Exp Med Biol 165B:305-308, 1984.

13. Yu AL*, Royston I, Lamb R, Kung F: Distribution of immunological subtypes of acute lymphoblastic leukemia in White and Mexican children. Prog Cancer Res Ther 27:157-162, 1984.
14. Yu J, Matsumoto S, Yu AL*: Inhibition of transcription as a mechanism of lymphocytotoxicity induced by deoxyadenosine and 2'-deoxycoformycin. Cancer Treat Symp 2:75-79, 1984.
15. Carson DA*, Wasson DB, Yu AL: Cell cycle independent lymphocytotoxicity of 2-Chloro-deoxyadenosine. Adv Exp Med Biol 165B:351-356, 1984.
16. Schulz G, Cheresch DA, Varki NM, Yu AL, Staffileno LK, Reisfeld RA*: Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 44:5914-5920, 1984.
17. Pattengale PK*, Sundstrom C, Yu AL, Levine A: Lysis of fresh leukemia blasts by interferon-activated human natural killer cells. Nat Immun Cell Growth Regulat 3:165-180, 1984.
18. Matsumoto SS, Yu AL*, Yu J: Morphological changes in leukemic lymphoblasts and normal lymphocytes treated with deoxyadenosine plus deoxycoformycin. Cancer Invest 3:225-233, 1985.
19. Niman HL, Thompson AMH, Yu AL, Markman M, Willems JJ, Herwig KR, Habib NA, Wood CB, Houghten A, Lerner RA*: Anti-peptide antibodies detect oncogene-related proteins in urine. Proc Natl Acad Sci 82:7924-7928, 1985.
20. Yu AL*, Mendelsohn J, Matsumoto SS: Induction of complete remission in T-cell acute lymphoblastic leukemia with deoxycoformycin and 9-B-D-arabinofuranosyladenine. Adv Exp Med Biol 195A:491-496, 1986.
21. Matsumoto SS, Yu AL*: Role of dATP in the inhibition of nucleic acid synthesis in isolated nuclei. Adv Exp Med Biol 195A:537- 540, 1986.
22. Wolff JA, Kulovich S, Yu AL, Qiao CN, Nyhan WL*: The effectiveness of benzoate in the management of seizures in nonketotic hyperglycinemia. Am J Dis Child 140:596-602, 1987.
23. Dillman RO*, Yu AL, Qiao CN: Repeated pentostatin (2'-deoxycofor-mycin)-induced remissions in a patient with advanced chronic lymphocytic leukemia. West J Med 148:334-337, 1988.
24. Matsumoto S, Yu J, Yu AL*: The effect of deoxyadenosine plus deoxycoformycin on replicative and repair synthesis of DNA in human lymphoblasts and isolated nuclei. J Bio Chem 263:7153-7158, 1988.
25. Yu J*, Shao L, Lemas V, Yu AL, Vaughan J, Rivier J, Vale W: Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature 330:765-767, 1987.

26. Winick N*, Buchanan GR, Murphy SB, Yu A, Boyett, J: Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission. A Pediatric Oncology Group Study. Med Ped Onc, 16:327-332, 1988.
27. Yu J*, Shao L, Vaughan J, Vale W, Yu A: Characterization of the potentiation effect of activin on human erythroid colony formation in vitro. Blood 73:952-960, 1989.
28. Yu J*, Lemas V, Page T, Connor JD, Yu AL: Induction of erythroid differentiation in K562 cells by inhibitors of inosine monophosphate dehydrogenase. Cancer Res 49:5555-5560, 1989.
29. Gjerset R, Yu AL, Haas M*: Establishment of continuous cultures of T-cell acute lymphoblastic leukemia cells at diagnosis. Cancer Res 50:10-14, 1990.
30. Haas M*, Yu A, Gjerset R: Characteristics of the leukemic cell in childhood acute lymphoblastic T-cell leukemia at diagnosis. Leukemia 4:230-234, 1990.
31. Hsiao RJ, Seeger RC, Yu AL, O'Connor DT*: Chromogranin A in children with neuroblastoma: Serum concentration parallels disease stage and predicts survival. J Clin Invest 85:1555-1559, 1990.
32. Yu J*, Maderazo L, Shao L-E, Frigon NL, Vaughan J, Vale W, Yu A: Specific roles of activin/inhibin in human erythropoiesis in vitro. Annals of the New York Academy of Sciences 628:199-211, 1991.
33. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA*: Effect of a chimeric anti-ganglioside GD₂ antibody on cell mediated lysis of human neuroblastoma cells. Can Res 51:144-149, 1991.
34. Barshop BA, Wolff J, Nyhan WL*, Yu A: Transcobalamin II deficiency presenting with methylmalonic aciduria and homocystinuria and abnormal absorption of cobalamin. Amer J of Medicine 35(2):222-228, 1990.
35. White CW, Wolf S, Korones D, Sondheimer HM, Tosi MF, Yu A*: Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. J Peds 118(1):59-66, 1991.
36. Adler MJ*, Hershberg R, Yu AL: Helper suppressor T-cell leukemia: unusual phenotype controlled with low-dose deoxycoformycin. Amer J of Hematology 36:208-210, 1991.
37. Saleh MN, Khazaeli MB, Wheeler RH, Allen L, Tilden AB, Grizzle W, Reisfeld RA, Yu AL, Gillies SD, LoBuglio AF*: phase I trial of the chimeric anti-GD₂ monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibod & Hybridomas 3:19-24, 1992.
38. Shao LE, Frigon NL, Young AL, Yu AL, Mathews LS, Vaughan J, Vale W, Yu J*: Effect of activin A on globin gene expression in purified human erythroid progenitors. Blood 79:773-781, 1992.

39. Shao LE, Frigon NL, Sehy DW, Yu AL, Lofgren J, Schwall R, Yu J*: Regulation of production of activin A in the human marrow stromal cells and monocytes. Exp Hematol 20:1235-1242, 1992.
40. Sehy DW, Shao LE, Yu AL, Yu J*: Activin A-induced differentiation in K562 cells is associated with a transient hypophosphorylation of Rb protein and the concomitant block of cell cycle at G₁ phase. J Cell Biochem 50:255-265, 1992.
41. Yeargin J, Cheng J, Yu AL, Gjerset R, Bogart M, Haas M*: P53 mutation in acute T- cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines. J Clin Invest 91:2111-2117, 1993.
42. Hsaio M, Yu AL, Ku D, Yeargin J, Yu J, Haas M*: Non-hereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood 83:2922-2930, 1994.
43. Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao LE, Yu AL*: Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 84:3105-3112, 1994.
44. Kung, FH*, Desai SJ, Dickerman J, Goorin AM, Harris MB, Inoue S, Krischer JP, Murphy SB, Pratt CB, Toledano S, Wiley JM, Yu AL: Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors in childhood. A Pediatric Oncology Group Phase I/II Study. Amer J Ped Hem/Onc 17:265-269, 1995
45. Uttenreuther MM, Huang CS, Reisfeld, RA, Yu AL*: Pharmacokinetics of anti-ganglioside GD2 Mab 14G2a in a phase I trial in pediatric cancer patients. Cancer Immunology and Immunotherapy 41:29-36, 1995.
46. Uttenreuther-Fischer MM, Huang C-S, Yu AL*: Pharmacokinetics of human/mouse chimeric anti-GD2 MAb ch14.18 in a phase I trial of neuroblastoma patients. Cancer Immunol and Immunother 41:331-338, 1995.
47. Diccianni M, Chau L, Batova A, Vu T, Yu A*: The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance. Cancer Letters 104:183-192, 1996.
48. Nobori T, Takabayashi K, Tran P, Orvis L, Batova A, Yu AL, Carson DA*: Genomic cloning of methylthioadenosine phosphorylase: A purine metabolic enzyme deficient in multiple different cancers. Proc Natl Acad Sci USA 93:6203-6208, 1996.
49. Batova A, Diccianni MB, Nobori T, Vu T, Yu J, Bridgeman L, Yu AL*: Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. Blood 88:3083-3090, 1996.
50. Bowman LC*, Castleberry RP, Cantor A, Joshi V, Cohn SL, Smith EI, Yu A, Brodeur GM, Hayes FA, Look AT: Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Can Instit 89:373-380, 1997.

51. Wallace MS*, Lee J, Sorkin L, Dunn JS, Yaksh T, Yu A: Intravenous lidocaine: effects on controlling pain after anti-GD₂ antibody therapy in children with neuroblastoma—a report of a series. Anesthesia and Analgesia 85:794-796, 1997.
52. Xiao WH, Yu AL, Sorkin LS*: Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD₂ ganglioside antibody. Pain 69:145-151, 1997.
53. Slart R, Yu AL, Yaksh TL, Sorkin LS*: An animal model of pain produced by systemic administration of an immunotherapeutic anti-ganglioside antibody. Pain 69:119-125, 1997.
54. Batova A, Diccianni MB, Yu JC, Nobori T, Link MP, Pullen J, Yu AL*: Frequent and selective methylation of p15 in addition to p16 deletion in T-cell acute lymphoblastic leukemia. Can Res 57:832-836, 1997.
55. Diccianni MB, Batova A, Yu J, Vu T, Pullen J, Amylon M, Pollock BH, Yu AL*: Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with P16/p15 deletions. Leuk Res 21:549-558, 1997.
56. Yu J, Batova A, Shao L-E, Carrera CJ, Yu AL*: Presence of methylthioadenosine phosphorylase (MTAP) in hematopoietic stem/progenitor cells: Its therapeutic implication for MTAP (-) malignancies. Clin Can Res 3:433-438, 1997.
57. Wong YF*, Chung TKH, Cheung TH, Nobori T, Yim SF, Lai KWH, Phil M, Yu AL, Diccianni MB, Li TZ, Chang AMZ: p16INK4 and p15 INK4B alterations in primary gynecologic malignancy. Gynecologic Oncology 65:319-324, 1997.
58. Page T, Yu A, Fontanesi J, Nyhan WL*: Developmental disorder associated with increased cellular nucleotidase activity. PROC Natl Acad Sci USA 94:11601-11606, 1997.
59. Yu AL*, Uttenreuther-Fischer MM, Huang C-S, Tsui CC, Gillies SD, Reisfeld RA, Kung FH: Phase I trial of a human-mouse chimeric anti-disialoganglioside (GD₂) monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clinical Oncology 16:2169-2180, 1998.
60. Diccianni MB, Omura-Minamisawa M, Batova A, Le T, Bridgeman L, Yu AL*: Frequent deregulation of p16 and p16/G1cell cycle regulatory pathway in neuroblastoma. International Journal of Cancer 80:145-154, 1999.
61. Batova A, Diccianni MB, Yu J, Carrera CJ, Bridgeman LJ, Kung FH, Pullen J, Amylon MD, Yu AL*: Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro. Can Res 59:1492-1497, 1999.
62. Amylon, MD*, Shuster J, Pullen H, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, Murphy SB: Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13:335-342, 1999.

63. Wong YF*, Chung TKH, Cheung TH, Nobori R, Yu AL, Yu J, Batova A, Lai KWH, Chang AMZ: Methylation of p16INK4A in primary gynecologic malignancy. Cancer Letters 139:231-235, 1999.
64. Batova A, Kamps A, Gillies SD, Reisfeld RA, Yu AL*: The Ch14.18-GM-CSF Fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin Can Res 5:4259-4263, 1999.
65. Omura-Minamisawa M, Diccianni MB, Batova A, Chang RC, Bridgeman L, Yu J, Pullen J, Bowman WP, Yu A*L: Universal inactivation of both p16 and p15 but not downstream components is an essential event in pathogenesis of T-cell acute lymphoblastic leukemia. Clin Can Res 6(4):1219-1228, 2000.
66. von Lintig FC, Huvar I, Law P, Diccianni MB, Yu AL, Boss GR*: RAS activation in normal white blood cells and childhood acute lymphoblastic leukemia. Clin Can Res 6(5):1804-1810, 2000.
67. M'soka TJ, Nishioka J, Taga A, Kato K, Kawasaki H, Yamada Y, Yu A, Komada Y, Nobori T*: Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T-cell acute lymphoblastic leukemia by real-time quantitative PCR assay. Leukemia 14(5):935-940, 2000.
68. Shao L-E, Dialynas DP, Yu AL, MacKintosh E, and Yu *: Human cord blood conditioned medium enhances leukemia colony formation in vitro. Leukemia Research 24:1041-1048, 2000.
69. Omura-Minamisawa M, Diccianni MB, Batova A, Chang RC, Bridgeman LJ, Yu J, de Wit E, Kung FH, Pullen, Yu AL*: *In vitro* sensitivity of T-cell lymphoblastic leukemia (T-ALL) to UCN-01 (7-Hydroxystaurosporine) is dependent on p16 protein status: A Pediatric Oncology Group (POG) Study. Cancer Research 60:6573-6576, 2000.
70. Dialynas DP, Lee M, Gold D, Shao L-E, Yu AL, Borowitz MJ and Yu J*: Pre-conditioning with fetal cord blood facilitates engraftment of primary childhood T-cell acute lymphoblastic leukemia in immunodeficient mice. Blood 97:3218-3225, 2001.
71. Omura-Minamisawa M, Diccianni MB, Chang RC, Batova A, Bridgeman L, Schiff J, Cohn S, London WB, Yu AL*: P16 /p14ARF cell cycle regulatory pathway in primary neuroblastoma: p16 expression is associated with advanced stage disease." Clinical Cancer Research 7:3481-3490, 2001.
72. Shao L, Diccianni MB, Tanaka T, Grippi R, Yu AL, Pullen, Camitta B, Yu J*: Thioredoxin Expression in Primary Childhood T-Cell Acute Lymphoblastic Leukemia and its Therapeutic Implication. Can Res 61:7333-7338, 2001.
73. Eliseeva E, Pati D, Diccianni M, Yu A, Mohsin S, Margolin J, Plon SE*: Expression and localization of the cdc34 ubiquitin confugating enzyme in pediatric acute lymphoblastic leukemia. Cell Growth & Differentiation 12:427-433, 2001.

74. Broome HE*, Yu AL, Diccianni M, Camitta BM, Monia BP, Dean NM: Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs. Leukemia Research 26:311-316, 2002.
75. Sorkin LS*, Yu AL, Junger H, Doom CM: Antibody directed GD2 produces mechanical allodynia, but not thermal hyperalgesia when administered systemically or intrathecally despite its dependence on capsaicin sensitive afferents. Brain Research 930:67-74, 2002.
76. Kletzel M*, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M, Geissler G, Marymount MA, Liu D, Kalapurakal J, Shore RM, Bardo DME, Schmoldt J, Rademaker AW, Cohn SL: Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem cell rescue: results of the Chicago pilot #2 study. J Clin Oncol 20:2284-2292, 2002.
77. Batova A, Shao, L-E, Diccianni MB, Yu AL*, Tanaka T, Rephaeli A, Nudelman A, Yu J: The Histone Deacetylase Inhibitor AN-9 has Selective Toxicity to Drug-Resistant Primary Leukemia and Cancer Cell Lines. Blood 100:3319-3324, 2002.
78. Houghton PJ*, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead G, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA: Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Can Res 8:3646-3657, 2002.
79. McGowan KA, Nyhan WL*, Barshop BA, Naviaux RK, Yu A, Haas RH, Townsend JJ: The role of methionine in ethylmalonic encephalopathy with petechiae. Archives of Neurology 61: 570-574, 2004.
80. Gebauer S, Yu AL*, Omura-Minamisawa M, Batova A, Diccianni MB: Expression profiles and clinical relationships of Id2, CDKN1B (p27) and CDKN2A (p16) in primary neuroblastoma. Genes, Chromosomes and Cancer 41:297-308, 2004.
81. Diccianni MB, Yu J, Meppelink G, de Vries M, Shao L-E, Gebauer G, Shih H, Roberts W, Kilcoin N, Pullen J, Carson DA, Yu A*: 3-amino thioacridone inhibits DNA synthesis and induces DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in a p-16 dependent manner. J Exp Therapeutics Oncology 4(3):223-237, 2004.
82. Loh KC*, Willert J, Meltzer W, Roberts W, Kerlin B, Kung F, Levy M, Kadota R, Yu A, Spear MA: Temozolomide and radiation for aggressive pediatric central nervous system malignancies. J Ped Hem Onc 27:254-258, 2005.
83. Batova A, Cottam H, Yu J, Diccianni MB, Carrera CJ, Yu AL*: 9- β -D-erythrofuransyladenine (EFA) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine. Blood 107(3):898-903, 2006
84. Ling TY, Kuo M D, Li CL, Yu AL, Huang YH.; Wu T J, Yu J*. Characterization and Identification of Pulmonary Stem Cells as Target for SARS-CoV Infection. Proc Natl Acad Sci 103, 9530-9535, 2006. (NSC 93-2751-B-001-001-Y)

85. Lin KI*, Kao YY, Kuo HK, Yang WB, Chou A, Lin HH, Yu AL, Wong CH: Reishi polysaccharides induce immunoglobulin production through the TLR4/TLR2-mediated induction of transcription factor blimp-1. J Biol Chem 281:24111-24123, 2006.
86. A Batova, T Lam, V Wascholowski, AL Yu, A Giannis and EA* Theodorakis . Synthesis and evaluation of caged Garcinia xanthenes. Org Biomol Chem. 5(3): 494-500, 2007.
87. Diccianni, MB, Chilcote R, Yu AL*. The genes of chromosome 9p21 (p16, p15, ARF, MTAP) in pediatric acute leukemia: Inactivation and exploitation for tumor-targeted therapeutics. Trends in Cancer Research. 2: 135-149, 2007.
88. Lin YC, Diccianni MB, Kim Y, Lin HH, Lee CH, Lin RJ, Joo SH, Li J, Chuang TJ, Yang AS, Kuo HH, Tsai MD, Yu AL*. Human p16 , a novel transcriptional variant of p16INK4A, co-expresses with p16INK4A in cancer cells and inhibits cell cycle progression. Oncogene. 26: 7017-7027 [May 7, Epub ahead of print], 2007.
89. Lin YC, Hsieh LC, Kuo MW, Yu J, Kuo HH, Lo WL, Lin RJ, Yu AL*, Li WH*. Human TRIM71 and its nematode homologue are both targets of let-7 microRNA and its zebrafish orthologue is essential for development. Molecular Biology and Evolution. 24: 2525-2534, 2007. (NSC 95-3114-P-002-Y)
90. Peng WP, Lin HC, Lin HH, Chu M, Yu AL, Chang HC and Chen CH*. Charge-Monitoring Laser-induced Acoustic Desorption Mass Spectrometry for Cell and Microparticle Mass Distribution Measurement. Angew. Chem. Int. Ed. 46(21): 3865-3869, 2007.
91. Chang YJ, Huang JR, Tsai YC, Hung JT, Wu D, Fujio M, Wong CH, and Yu AL*. Potent Immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci. 104(25): 10299-10304, 2007.
92. Nie Z, Cui F, Tzeng YK, Chang HC*, Chu M, Lin HC, Chen CH, Lin HH, Yu AL. High-speed mass analysis of whole erythrocytes by charge-detection quadrupole ion trap mass spectrometry. Analytical Chemistry. 79: 7401-7407, 2007 (NSC 92-3112-B-001-012-Y)
93. Peng WP, Lin HC, Chu ML, Chang HC, Lin HH, Yu AL, Chen CH. Charge monitoring cell mass spectrometry. Analytical Chemistry. 80(7): 2524-2530, 2008.
94. Yang HC*, Huang MC, Li LH, Lin CH, Yu AL, Diccianni MB, Wu JY, Chen YT, Fann CSJ*. MPDA: Microarray pooled DNA analyzer. BMC Bioinformatics. 9: 196, 2008
95. Lin, YC, Kuo, MW, Yu, J, Kuo, HH, Lin, RJ, Lo, WL, Yu AL*, c-Myb is an Evolutionary Conserved miR-150 Target and miR-150/c-Myb Interaction is Important for Embryonic Development. Molecular Biology and Evolution, 25(10): 2189-2198, 2008 (published ahead of print July, 2008) (NSC 685032)
96. Chang WW, Lee CH, Lee P, Lin J, Hsu CW, Hung JT, Lin JJ, Yu J, Wong CH, Yu JC, Shao LE, Yu AL*. Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 & 2 in Globo H synthesis. Proc Natl Acad Sci. 105(33): 11667-11672, 2008 (published ahead of print August 6, 2008; cited by Research

Highlights Glycopharmacology: New directions. Nature Functional Glycomics, 11 September 2008)

97. Wang CC, Huang YL, Ren CT, Lin CW, Hung JT, Yu JC, Yu AL, Wu CY, Wong CH*. Glycan Microarray of Globo H and Related Structures for Quantitative Analysis of Breast Cancer. Proc Natl Acad Sci. 105: 11661-11666, 2008
98. Chen MW, Cheng TJR, Huang Y, Jan JT, Ma SW, Yu AL, Wong CH*, Ho DD. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci. 105: 13538-13543, 2008
99. Huggins R*, Lin YC*, Li LH, Yu AL, Yang HC. Nonparametric estimation of LOH using Affymetrix SNP genotyping arrays for unpaired samples. Journal of Human Genetics. 53:983-990, 2008
100. Gilman AL*, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH, Sondel PM. Phase I Study of ch14.18 with GM-CSF and IL-2 in Children with Neuroblastoma Following Autologous Bone Marrow Transplant or Stem Cell Rescue A Report from the Children's Oncology Group. J. Clinical Oncology. 27(1): 85-91, 2009
101. Lee CH, Chou TC, Su TL, Yu J, Shao LE, Yu Alice L*. BO-0742, a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors . Cancer Letters 276:204-211, 2009 (NSC 96-2323-B-001-004)

BOOKS AND MONOGRAPHS

1. Sobol RE, Dillman RO, Beauregard JC, Yu AL, Lee JW, Collins H, Wormsley S, Green MR, Ellison RR, Royston I: Clinical utility of monoclonal antibodies in phenotyping acute and chronic lymphocytic leukemia. In Protides of the Biological Fluid. 30th Colloquim, Edited by H. Peters. Pergamon Press, Oxford, England. 417-422, 1983.
2. Yu AL, Mendelsohn J, Matsumoto: Induction of complete remission in T-cell acute lymphoblastic leukemia with deoxycoformycin (dcf) and 9-arabinofuranosyladenine (ara-A) In Purine and Pyrimidine Metabolism in Man V, pp. 491-496. Edited by WL Nyhan, LF Thompson, RWE Watts. Plenum Press, New York, 1986.
3. Matsumoto SS, Yu, AL: Role of dATP in the inhibition of nucleic acid synthesis in isolated nuclei. In Purine and Pyrimidine Metabolism in Man V, pp. 537-540. Edited by WL Nyhan, LF Thompson, RWE Watts. Plenum Press, New York,
4. Page T, Nyhan WL, Yu AL, Yu J: A syndrome of megaloblastic anemia, immunodeficiency, and excessive nucleotide degradation. In Purine and Pyrimidine Metabolism in Man VII, Part B, pp. 345-348. Edited by R.A. Harkness et al. Plenum Press, New York, 1991.
5. Reisfeld RA, Mueller BM, Handgretinger, Yu AL, Gillies SD: Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotherapy. In Biological Function of Gangliosides, Chapt. 15, pp. 201-212, Progress in Brain Research Vol. 101.

Edited by L Svennerholm, AK Asbury, RA Reisfeld, K Sandhoff, K Suzuki, G Tettamanti, G. Toffano. Elsevier, New York, 1994.

6. Reisfeld RA, Mueller BM, Handgretinger R, Yu AL, Gillies SD: Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotherapy in *Progress in Brain Research. Biological Function of Gangliosides* (1994), Elsevier Science Ltd., Amsterdam, The Netherlands. pp.201-212
7. Page T, Barshop B, Yu AL, Nyhan WL: Treatment of Lesch-Nyhan syndrome with AICAR. *In Purine and Pyrimidine Metabolism in Man VIII*, pp. 353-356. Edited by A. Sahota and M. Taylor, Plenum Press, New York, 1995.
8. Burns JC, Yu JK, Yu AL: Methods for producing high-titer, pantropic retroviral vectors for gene transfer into leukemic T-cells. *In Methods in Gene Therapy: Gene Therapy Protocols*, Chapt. 15, pp. 213-221. Edited by Paul D. Robbins. Humana Press, Totowa, New Jersey, 1996.
9. Yu AL, Chen J, Diccianni MB, Batova A, Yu J: Exploitation of frequent p16 deletion in the treatment of T-cell acute lymphoblastic leukemia. *In Molecular Biology of Hematopoiesis*, Chapter 31, pp. 247-256. Edited by N.G. Abraham, S. Asano, G. Brittenger, R. Shaddock. Plenum Press, New York, 1996.
10. Page T, Yu AL, Fontanesi J, Nyhan WL: A syndrome of seizures and pervasive developmental disorder associated with excessive cellular nucleotidase activity. *In Purine and Pyrimidine Metabolism in Man IX*, Chapter 151, pp. 789-792. Edited by Griesmacher et al., Plenum Press, New York, 1998.
11. Cheung N-KV, Yu AL: Immunotherapy of Neuroblastoma. *In Neuroblastoma*, Chapter 40, pp. 541-549. Edited by G.M. Brodeur, T. Sawada, Y. Tsuchida and P.A. Voûte. Elsevier Science B.V., Amsterdam, The Netherlands, 2000.

ABSTRACTS

1. Yu AL, Cohen EP: The isolation of thymus-leukemia (TL) antigens and their metabolism during antigenic modulation. *Fed Proc* 32:4448, 1973.
2. Yu AL, Cohen EP: The appearance of TL(+) murine leukemias which resist antibody-induced lysis. *Proc Amer Soc Microbiol* 73:M229, 1973.
3. Yu AL, Cohen EP: The effect of specific antisera on the metabolism of membrane-associated antigens of murine leukemic cells. *J Cell Biol* 59:747, 1973.
4. Yu AL, Cohen H, Watts HG, Jaffe N, Nathan D, Parkman R: Presence of "cytotoxic" and "inhibitory" lymphocytes in patients with osteogenic sarcoma. *Proc ASCO* 17:C254, 1976.
5. Yu AL, Kung FH, Nissinen E, Bakay B: Effect of deoxycoformycin and deoxyadenosine on DNA synthesis of human T-cell leukemia. *Proc AACR* 20:184, 1979.

6. Koenig HM, Nelson DP, Lightsey AL, Ritchey AK, Hoffman R, Kung FH, Yu AL, Hartman GA, Diamond LH: Normal erythroid colony growth in congenital hypoplastic anemia (CHA) without corticosteroids. Blood 54:71a, 1979.
7. Yu AL, Kung FH, Bakay B, Nyhan WL: Preliminary trial of deoxycoformycin in human T-cell leukemia. J Clin Chem Clin Biochem 17:451-452, 1979.
8. Yu AL, Millan JJ, Kung FH, Fishman WH: The value of some oncodevelopmental markers in monitoring two patients with hepatoblastoma. Clin Res 28:107A, 1980.
9. Wolf P, Koett J, Kung FH, Yu AL: Leukemia hypocalcemia. Clin Chem 26:1037, 1980.
10. Yu AL, Leung KL, Kung FH, Sobol RE, Royston I: Utility of monoclonal antibodies in the immunologic phenotyping of acute lymphoblastic leukemia (ALL). Proc ASCO 22:C302, 1981.
11. Leung KL, Yu AL: Natural killing (NK) activity in T-cell chronic lymphocytic leukemia (T-CLL) treated with deoxycoformycin (dcf). Proc ASCO 22:1098, 1981.
12. Yu AL, Bakay B, Matsumoto S, Nyhan WL, Green M, Royston I: The effects of deoxycoformycin (dcf) on T-cell chronic lymphocytic leukemia (CLL). Proc AACR 22:894, 1981.
13. Yu AL, Sweetman L, Nyhan WL: The pathogenetic mechanism of recurrent mucocutaneous candidiasis in a patient with methylmalonic acidemia. Clin Res 29:124A, 1981.
14. Matsumoto S, Bakay B, Nyhan W, Yu AL: Differential effects of deoxyadenosine on human leukemias. Blood 58:434, 1981.
15. Yu AL, Matsumoto S, Bakay B, Nyhan WL, Kung FH: Biochemical basis of differential effects of deoxyadenosine on human leukemias. J Clin Chem Clin Biochem 20:438-439, 1982.
16. Pattengale PK, Yu AL, Sundstrom C, Wigzell H: Lysis of fresh acute leukemia cells by interferon-activated human natural killer (NK) cells. J Cell Biochem 8:103, 1982.
17. Carson DA, Wasson DB, Yu AL: Cell cycle independent lymphocytotoxicity of 2-Chloro-deoxyadenosine. J Clin Chem Clin Biochem 20:356, 1982.
18. Matsumoto S, Yu AL: Deoxyadenosine toxicity to non-dividing lymphocytes. 13th Internatl Cancer Congress 3794, 1982.
19. Matsumoto S, Yu AL, Yu J: Morphological changes in human T-lymphoblasts induced by deoxyadenosine (dADO) plus deoxycoformycin (dcf). Proc AACR 24:1207, 1983.
20. Yu AL, Matsumoto S, Levey D, Yu J: Inhibition of transcription as a mechanism of lymphocytotoxicity in ADA deficiency. J Cell Biochem Suppl 7B:503, 1983.

21. Matsumoto S, Yu J, Yu AL: Nucleotide-dependent inhibition of transcription in T-lymphoblasts by deoxyadenosine plus deoxycoformycin. Proc AACR 25:41, 1984.
22. Yu AL, Qiao CN, Krance R, Matsumoto SS: Intraleural administration of deoxycoformycin in T-cell lymphoma with malignant effusion. Blood 64:647A, 1984.
23. Yu J, Yu AL, Singh M: Detection of a 70,000 dalton protein in the differentiated K-562 cells and erythroblasts of human bone marrow. Blood 64:486A, 1984.
24. Yu AL, Staffileno LK, Castleberry RP, Schulz G, Reisfeld RA: Use of a neuroblastoma monoclonal antibody in therapeutic monitoring of neuroblastoma patients. Proc ASCO 4:C951, 1985.
25. Yu AL, Qiao CN, Krance R, Matsumoto SM: Clinical and biochemical consequences of intravenous (IV) and intraleural (IP) administration of deoxycoformycin (dcf). Proc AACR 26:628, 1985.
26. Matsumoto SS, Yu AL: Role of dATP in the inhibition of nucleic acid synthesis in isolated nuclei. Ped Res 19:129, 1985.
27. Yu AL, Mendelsohn J, Matsumoto S: Induction of complete remission in T-ALL by deoxycoformycin (dcf) and ARA-A. Ped Res 19:236, 1985.
28. Winick N, Buchanan G, Murphy SB, Yu AL: Deoxycoformycin in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) early in second remission. Blood 66:731, 1985. Also in Proc ASCO 6:599, 1987.
29. Yu AL, Qiao CN, Dillman RO, Matsumoto SS: In vitro parameters which may predict clinical response of chronic lymphocytic leukemia (CLL) to deoxycoformycin (dcf). Proc AACR 27:777, 1986.
30. Yu AL, Matsumoto SS, Dillman RO, Qiao CN: Biochemical consequences of deoxycoformycin (dcf) treatment in chronic lymphocytic leukemia (CLL). Proc AACR 27:1206, 1986.
31. Yu AL, Qiao CN, Garg A, Kung F: In vivo and in vitro changes in lineage expression of acute leukemia associated with t(4;11) translocation. Proc ASCO 6:609, 1987.
32. Matsumoto S, Yu JC, Yu AL: The effect of deoxyadenosine (dado) plus deoxycoformycin (dcf) on repair DNA synthesis. Proc AACR 28:1, 1987.
33. Yu AL, Matsumoto SS, Qiao CN, Friedland A: Comparison of cytotoxic effects of 9-B-D-arabinofuranosylguanine (ara-G) and 2-deoxyadenosine (dado) on chronic lymphocytic leukemia (CLL). Leukemia 1:26, 1987.
34. Yu AL, Connor JD, Page T, Lemas V, Yu J: Ribavirin causes induction of erythroid differentiation in human cell line, K562. Leukemia 2:198, 1988.

35. Yu AL, Connor JD, Page T, Lemas V, Yu J: Induction of hemoglobin accumulation in human K562 cells by inhibitors of inosine monophosphate dehydrogenase. Proc AACR 29:127, 1988.
36. Yu AL, Jiminez R, Qiao CN, Friedland A: Cytotoxic effects of 9-B-arabino-furanosylguanine (ara-G) on chronic lymphocytic leukemia (CLL). Proc AACR 29:1381, 1988.
37. Marshall M, Wootton SL, Sartoris DJ, Ramos E, Yu AL, Nyhan WL, Stein JA, Mazess RB, Resnick D: Dual-energy radiographic absorptiometry of the lumbar spine and proximal femur: clinical experience in children and adolescents. Presented only at the 74th Scientific Assembly Annual Meeting of the Radiological Society of North America, Chicago, Illinois, November 27-December 2, 1988 (never published in any journal, etc., as an abstract or part of an article).
38. Yu J, Shao L, Vaughan J, Vale W, Yu AL: Specific role of activin, a TGB-Beta-like protein, in the colony formation of human erythroid progenitors in vitro. J Cell Biol 107:49a, 1988.
39. Yu J, Shao L, Vaughan J, Vale W, Yu AL: Characterization of the potential effect of activin on human erythroid colony formation in vitro. Blood 72:106a, 1988.
40. Yu J, Shao L, Vaughan J, Vale W, Yu AL: Specific potentiation of erythroid progenitors in vitro by activin. J Cell Biochem 13c:22, 1989.
41. Gjerset J, Yu AL, Haas M: Establishment of continuous cultures of T-cell acute lymphoblastic leukemia cells at diagnosis. J of Cell Biochem E326:124, 1989.
42. White CW, Wolf SJ, Bowers JT III, Leventhal JP, Yu A: Interferon alpha therapy for pulmonary angiomatous disorders. American Review of Respiratory Disease (Supplement), 141 (No. 4, Part 2):A888, 1990.
43. Yu J, Frigon NL, Shao L, Maderazo L, Vaughan J, Vale W, Yu A: Increase of globin mRNAs in human erythroid cells by activin. J Cell Biochem 14E:67, 1990.
44. Bowman LC, Castleberry RP, Altshuler G, Smith EI, Cantor A, Shuster J, Yu AL, Look AT, Hayes FA: Therapy based on DNA index (DI) for infants with unresectable and disseminated neuroblastoma (NB): Preliminary results of the pediatric oncology group "Better Risk" study. International Society of Paediatric Oncology (SIOP) XXII Meeting, 1990.
45. Yu J, Frigon NL, Shao L, Yu AL: Regulation of human erythropoiesis in vitro by activin. Blood 76:173a (No. 10, Suppl 1), 1990.
46. Yu AL, White CW, Kung FH: Malignant degeneration of lymphangioma and its response to alpha-interferon. Blood 76:225a (No. 10, Suppl 1), 1990.
47. Yu AL, Reisfeld RA, Gillies SD: Immune response to monoclonal antibody therapy. Proc AACR 32:1566, 1991.

48. Yu AL, Gillies SD, Reisfeld RA: Phase I clinical trial of Ch14.18 in patients with refractory neuroblastoma. Proc ASCO 10:1118, 1991.
49. Shao LE, Frigon NL, Yu AL, Losgren J, Schwall R, Yu J: Regulation of production of activin A in the human marrow stromal cells and monocytes. Blood 78:397, 1991.
50. Kung FH, Goorin AM, Harris MB, Krischer JP, Pratt CB, Wiley JM, Yu AL: Ifosfamide (I)/carboplatin(C)/etoposide(E) in children with recurrent/resistent malignant solid tumors. Proc AACR 33:1545, 1992.
51. Uttenreuther M, Huang CS, Tsui C, Reisfeld RA, Gillies SD, Yu AL: Comparison of biological activity and pharmacokinetics between a mouse and a human-mouse anti-GD2 chimeric monoclonal antibody (MAB). Proc AACR 33:1461, 1992.
52. Huang CS, Uttenreuther M, Reisfeld RA, Yu AL: Immunotherapy of GD2 (+) tumors with a murine monoclonal antibody (MAB) 14G2a: A phase I study. Proc ASCO 11:1254 (p21), 1992.
53. Bowman L, Castleberry R, Altshuler G, Joshi V, Smith E, Cantor A, Shuster J, Yu A, Look A, Brodeur G, Hayes F: Therapy based on DNA index (DI) for infants with unresectable and disseminated neuroblastoma (NB): the Pediatric Oncology Group "Better Risk" study. Proc ASCO 11:1257, 1992.
54. Uttenreuther MM, Huang CS, Reisfeld RA, Yu AL: Pharmacokinetics of chimeric anti-GD2 human-mouse antibody Ch14.18 in a phase I clinical trial with neuroblastoma patients. J Cancer Research and Clinical Oncology 118:V4.10.03, 1992.
55. Yu AL, Hsiao M, Cheng J, Yeargin R, Gjerset R, Haas M: Non-hereditary p53 mutations in relapse T-cell acute lymphoblastic leukemia (T-ALL). 24th Congress of the International Society of Haematology 402:1523, 1992.
56. Hsiao M, Yeargin J, Dorn E, Yu A, Haas M: p53 mutations in childhood T-cell acute lymphoblastic leukemia. p53 Workshop, Tiberias, Israel, November 1-5, 1992.
57. Uttenreuther M, Reisfeld RA, Yu AL: A pilot study of chimeric Mab ch14.18 and GM-CSF in neuroblastoma. Antibody Immunoconjugates, and Radiopharmaceuticals 6:42, 1993.
58. Uttenreuther MM, Reisfeld RA, Yu AL: Preliminary data on a phase II trial of chimeric anti-GD2 MAb ch14.18 and GM-CSF in neuroblastoma. PROC AACR 34:1329, 1993.
59. Kung FH, Goorin AM, Harris MB, Krischer JP, Pratt CB, Wiley JM, Yu AL: Ifosfamide/carboplatin/etoposide (ICE) in children with recurrent/resistant malignant solid tumors. PROC AACR 34:1372, 1993.
60. Yu AL, Kurtzberg J, Buchanan G, Vietti T: Treatment of first relapse of childhood acute T-lymphoblastic leukemia (T-ALL)/T-lymphoma with combination chemotherapy including 2'deoxycoformycin (dcf.). PROC ASCO 12:1068, 1993.

61. Diccianni M, Yu AL, Yu J: The essential role of p53 in relapse T-ALL. Blood 82:194, 1993.
62. Yu AL, Heung RC, Uttenreuther M, Kim J, Link MP, Ochs J, Buchanan GR, Amylon M, Vietti T: Phase I trial of XomaZyme-H65 (H65-RTA) in children with T-cell acute lymphoblastic leukemia/lymphoma: A Pediatric Oncology Group (POG) study (POG 9074). PROC AACR 35:1262, 1994.
63. Diccianni MB, Yu J, Yu AL: P53 mutations are associated with poor clinical outcome in T-cell acute lymphoblastic leukemia (T-ALL). PROC AACR 35:1296, 1994.
64. Lozinski GM, Yu AL, Yee J-K, Friedmann T, Yu J, Burns JC: Pseudotyped retroviral vector-mediated gene transfer into human leukemic cells. Clin Res 42:56, 1994.
65. Yu A, Page T, Nyhan WL: A syndrome of abnormal speech and behavior, seizures, altered susceptibility to infection, and excessive nucleotide catabolism. Clin Res 42:87A, 1994.
66. Kung FH, Desai S, Goorin AM, Harris MB, Krischer JP, Murphy SB, Pratt CB, Wiley JM, Yu AL: Ifosfamide/carboplatin/etoposide (ICE) in recurrent malignant non-Hodgkin's lymphoma of childhood. PROC ASCO 13:1333, 1994.
67. Heung RC, Kim J, Uttenreuther M, Vietti T, Yu AL: Antigenic modulation by anti-CD5 immunoconjugate and relative resistance of H65-ricin chain A immunoconjugate in patients with relapsed T-cell acute lymphoblastic leukemia. Antibody and Immunoconjugates and Radiopharmaceuticals 7:92, 1994.
68. Burns JC, Lozinski GM, Yee J-K, Friedman T, Yu J, Yu AL: Pseudotyped retroviral vector-mediated gene transfer into human leukemic cells. Ped Res 35:934, 1994.
69. Diccianni MB, Gregoroff J, Yu AL: Mutations of the p16 tumor suppressor gene in T cell acute lymphoblastic leukemia. PROC AACR 36:3455, 1995.
70. Uttenreuther MM, Reisfeld RA, Yu AL: Pilot-study on chimeric human/mouse anti-disialosialoside (GD2) monoclonal antibody (Mab) ch14.18 and GM-CSF in neuroblastoma. Monatsschr Kinderheilkd 142:927, 1994. Also submitted to the 13th Meeting of the European Association for Cancer Research, Berlin, Germany, Sept. 25-28, 1994. Included are German and English versions.
71. Uttenreuther-Fischer MM, Reisfeld RA, Yu AL: Summary of three phase I/II trials using anti-disialosialoside (GD2) monoclonal antibodies in neuroblastoma-therapy. J Cancer Res Clin Oncol (Suppl 2) 121: MS 5-9, 1995.
72. Yu AL, Uttenreuther MM, Kamps A, Batova A, Reisfeld RA: Combined use of a human-mouse chimeric anti-GD2 (ch14.18) and GM-CSF in the treatment of refractory neuroblastoma. Antibody Immunoconjugates, and Radiopharmaceuticals 8:12, 1995.
73. Yu AL, Chen J, Diccianni MB, Batova A, Yu J: Exploitation of selective methionine dependency and frequent p16 deletion in the treatment of T-cell leukemia. Acta Hematologica 93:4/14, 1995.

74. Yu AL, Diccianni MB, Batova A, Vu T, Pullen J, Amylon M, Pollock B, Yu J: High frequency alterations of the p16 and p15, but not p18, CDK inhibitors in T cell acute lymphoblastic leukemia. Blood 86:1057, 1995.
75. Wallace M, Sorkin LS, Lee J, Laitin S, Yu A, Dunn J, Yaksh TL: Effect of pretreatment with lidocaine on pain following anti-GD2 ganglioside antibody for pediatric neuroblastoma. 14th Annual American Pain Society Meeting 95805:A-109, 1995.
76. Sorkin LS, Slart R, Yaksh TL, Yu AL: New pain model induced by a monoclonal antibody, chemotherapeutic agent. Soc for Neuroscience 21:459.4, 1995.
77. Batova A, Diccianni MB, Nobori T, Vu T, Yu J, Bridgeman L, Yu AL: Frequent deletion in the methylthioadenosine phosphorylase (MTAP) gene in T-cell acute lymphoblastic leukemia (T-ALL): strategies for enzyme-targeted therapy. PROC AACR 37:2878, 1996.
78. Diccianni MB, Chau L, Vu T, Yu AL: The p16 and p18 tumor suppressor genes in neuroblastoma and T-cell leukemia. PROC AACR 37:4045, 1996.
79. Diccianni MB, Batova A, Vu T, Pollock B, Yu AL: Clinical significance of p16 gene deletions in T-cell acute lymphoblastic leukemia. PROC AACR 37:4046, 1996.
80. Uttenreuther-Fischer MM, Reisfeld RA, Yu AL: Ergebnisse dreier Phase-I-II-Studien mit monoklonalen anti-Disialogangliosid (GD2) Antikörpern bei Neuroblastomerkrankung. 22. Deutscher Krebskongress, Berlin, 20.-24., Februar 1996. (in German)
81. Yu J, Batova A, Shao LE, Yu AL: Exploitation of frequent deletion in the methylthioadenosine phosphorylase (MTAP) gene in the treatment of T-cell acute lymphoblastic leukemia (T-ALL). Experimental Hematology 24:1124 (544), 1996.
82. Uttenreuther-Fischer MM, Yu A, Gaedicke G, Fischer P: A human anti-idiotypic monoclonal antibody against anti-GD2 chimeric antibody ch14.18 from a patient treated for neuroblastoma. Human Antibodies & Hybridomas 7:2, 1996.
83. Uttenreuther-Fischer MM, Yu A, Gaedicke G, Fischer P: Is the clinical efficacy of anti-GD₂ monoclonal antibodies (MAb) in the treatment of neuroblastoma due to CDC and ADCC, or to the activation of the idiotypic network? Immunobiology 196:1-3: Page 30, 1996.
84. Uttenreuther-Fischer MM, Fischer P, Reisfeld RA, Gaedicke G, Yu AL: Monoclonal anti-disialoganglioside (GD2) antibodies in neuroblastoma-therapy: Summary of three phase I/II trials. 1st International Symposium on Minimal Residual Cancer, 06/23-25/96, Munich, Germany, Poster Session V.
85. Yu AL, Batova A, Diccianni MB, Pullen J, Link MP, Yu J: Preferential inactivation of p15^{INK4B} but not p16^{INK4A} by hypermethylation in T-cell acute lymphoblastic leukemia. Blood 88:1408, 1996.

86. Batova A, Diccianni MB, Yu JC, Nobori T, Link MP, Pullen J, Yu AL: Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia (T-ALL). PROC AACR 38:1855, 1997.
87. Omura-Minamisawa M, Diccianni MB, Batova A, Dixon CG, Le T, Yu AL: Multiple mechanisms of cell cycle deregulation in neuroblastoma: Involvement of p16, p15, p53, CDK4 and cyclin D2. PROC AACR 38:1826, 1997.
88. Diccianni MB, Batova A, Omura-Minamisawa M, Chau LS, Yu AL: Frequent and differential overexpression of p16 and p15 in neuroblastoma. PROC AACR 38:3317, 1997.
89. Yu AL, Batova A, Alvarado C, Rao VJ, Castleberry RP: Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: A POG phase II study. PROC ASCO 16:1846, 1997.
90. Yu AL, Page T, Fontanesi J, Lawton D, McArthur C, Nyhan W: Pyrimidine responsive syndrome of neurologic dysfunction and susceptibility to infection. Ped Res 41:639, 1997.
91. Page T, Fontanesi J, Yu A, Nyhan W: A syndrome of seizures and pervasive developmental delay associated with excessive cellular nucleotidase activity. Clin Biochem 80:123, 1997.
92. Omura-Minamisawa M, Diccianni MB, Batova A, Pullen J, Bowman WP, Yu AL: Inactivation of p16 cell cycle regulatory pathway by specific targeting of p16 but not the downstream components in T-cell acute lymphoblastic leukemia (T-ALL): A Pediatric Oncology Group. Study. Blood 90:2190, 1997.
93. Diccianni MB, Omura-Minamisawa M, Batova A, Bridgeman L, Yu AL: Frequent deregulation of p16 and the G1 cell cycle control pathway in neuroblastoma. PROC AACR 39:3003, 1998.
94. Batova A, Diccianni MB, Yu J, Bridgeman L, Pullen J, Amylon MD, Yu AL: Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro. PROC AACR 39:3195, 1998.
95. Kletzel M, Cohn SL, Morgan E, Pirich L, Marymount MA, Haut P, Yu A: Triple tandem peripheral blood stem cell (PBSC) rescue for children with high risk (HR) neuroblastoma (NB). Results of a pilot trial. Medical and Pediatric Oncology (31) 4:017, page 194, 1998.
96. Omura-Minamisawa M, Diccianni MB, Batova A, Bridgeman L, Yu AL: Alterations of p16 cell cycle regulatory pathway in primary neuroblastoma: A Pediatric Oncology Group (POG) study. PROC AACR 40:1864, 1999.
97. Diccianni MB, Omura-Minamisawa M, Batova A, Bridgeman L, Yu AL: Loss of p15 expression in advanced stage neuroblastoma: A Pediatric Oncology Group (POG) study. PROC AACR 40:1865, 1999.
98. Yu J, Dialynas DP, Shao L-E, Lee M-J, Gold DP, Yu AL: Fetal cord blood engraftment of primary childhood T-cell acute lymphoblastic leukemia in immunodeficient mice and enhances leukemia colony formation in vitro. PROC AACR 40:4352, 1999.

99. McGowan KA, Barshop BA, Naviaux RK, Haas RH, Yu A, Nyhan WL: Ethymalonic encephaloowopathy with petechiae: reduction in ethymaloonic acid excretion with methionine restriction and delineation of coagulopathy. J Invest Med 47:24A, 1999.
100. Broome HE, Yu AL, Diccianni MB, Pullen J, Monia BP: Inhibition of BCL-xL expression sensitizes T-cell acute lymphocytic cells to chemotherapeutic drugs. Blood 94:226b (Abst 4214), 1999.
101. Omura-Minamisawa M, Diccianni MB, Batova A, Chang RC, Bridgeman L, Yu AL: Toxicity of UCN-01 in T-ALL is dependent on p16 protein status: A Pediatric Oncology Group (POG) study. PROC AACR 41:314 (abst 1994), 2000.
102. M'soka TJ, Nishioka J, Taga A, Kato K, Kawasaki H, Yamada Y, Yu A, Komada Y, Nobori T: Detection of methylthioadenosine phosphorylase and p16 gene deletion in T-cell acute lymphoblastic leukemia by real-time quantiative PCR assay. PROC AACR 41:758 (abst 4819), 2000.
103. Batova A, Shao L-E, Yu AL, Rephaeli A, Yu J: Therapeutic efficacy of a novel butyric acid pro-drug for T-cell acute lymphoblastic leukemia in vitro. PROC AACR 42:212 (abst 1138), 2001.
104. Yu AL, Eskenazi A, Strother D, Castleberry R : A pilot study of anti-idiotypic monoclonal antibody as tumor vaccine in patients with high risk neuroblastoma. PROC ASCO 20:368a (Abst 1470), 2001.
105. Tanaka T, Shao L-E, Diccianni MB, Gribi R., Yu AL, Yu J: Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication. Exp Hemat 29:24 (Abst 90), 2001.
106. Yu AL, Meppelink G, De Vries M, Yu J, Shao L-E, Gebauer S, Shih H, Carson DA, Diccianni MB: Primary T-ALL is a useful model for preclinical screening of small molecule inhibitors of CDK4. Blood 98(11):117a (abst 492), 2001.
107. Shao L-E, Tanaka T, Diccianni MB, Gribi R, Yu AL, Yu J: Analysis of thioredoxin expression in childhood primary T-cell Acute lymphoblastic leukemia. Blood 98(11):319a (abst 1346), 2001.
108. Batova A, Strother D, Castleberry R, Eskenazi AE, Yu AL: Immune responses to an anti-idiotypic monoclonal antibody 1A7 as a tumor vaccine in children with high risk neuroblastoma. PROC AACR 43:143 (abst 713), 2002.
109. Diccianni MB, Gebauer S, Meppelink G, Yu J, Shao L-E, Shih H, Carson,DA, Yu AL: Small molecule inhibitors of cyclin dependent kinase are effective inhibitors of DNA synthesis and viability in T-ALL. PROC AACR 43:4880, 2002.
110. Gebauer S, Diccianni M, Gebauer G, Yu A: P16 expression is not correlated with expression of Id2 or the loss of p27kip1 at protein level in advanced stage Neuroblastoma. PROC AACR 43:624 (abst 3099), 2002.

111. Yu J, Shao L-E, Tanaka T, Gribi R, Raetz E, Carroll WL, Yu AL: A murine model of primary human leukemia for studying leukemia-stromal interactions. PROC AACR 43:486 (abst 2416), 2002.
112. Gebauer S, Diccianni MB, Omura-Minamisawa M, Cohn SL, Seeger R, Yu AL: P16 expression is associated with advanced stage neuroblastoma and not correlated with expression of Id2: A Children's Oncology Group study. SFOP, Société Française d'Oncologie Pédiatrique, Advances in Neuroblastoma 2002 Conference PC-08:Page 110, 2002.
113. Yu AL, Batova A, Strother D, Eskenazi A, Castleberry R, Bash R, Matthay K, Diller L: A pilot trial of a GD-2 directed anti-idiotypic antibody as a vaccine for high risk neuroblastoma. SFOP, Société Française d'Oncologie Pédiatrique, Advances in Neuroblastoma 2002 Conference OC-16:Page 44, 2002.
114. Diccianni MB, Yu J, Yu AL: The cyclin dependent kinase inhibitor 3-aminothioacridone inhibits DNA synthesis in a p16 and pRb protein-status dependent manner and induces DNA strand breaks in T-cell acute lymphoblastic leukemia. PROC AACR 44:712 (abst 3117), 2003.
115. Diccianni MB, Shue EH, Pollock BH, Yu AL: Expression of Hox 11 but not Hox 11L2 is associated with relapsed T-Cell acute lymphoblastic leukemia. Blood 102(11):22a (abst 168), 2003.
116. Diccianni MB, Pollock BH, Shue EH, Yu AL, Asselin B: Hox11, Hox11L2 and LYL1 expression and treatment failure in T-cell acute lymphoblastic leukemia (T-ALL). PROC AACR 45:99 (abst 435), 2004.
117. Yu J, Shao L-E, Huang C-L, Yu AL: A predictive murine model of human primary leukemia for preclinical drug testing and delineation of leukemia stem cells. PROC AACR 45:155 (abst 671), 2004.
118. Yu AL, Batova A, Gribi R, Diccianni L, Geske D, London W, Gilman A, Ozkaynak F: Antibody-dependent cellular cytotoxicity (ADCC) in COG ANGL0032: A phase III randomized trial of chimeric anti-GD₂ and GM-CSF/IL2 in high risk neuroblastoma following myeloablative therapy and autologous stem cell transplant (ASCT). PROC ASCO 23:183 (Abst 2582) 2004.
119. Batova A, Yu AL, Strother D, Angelini P, Eskenazi A: Promising results of a pilot trial of GD₂ directed anti-idiotypic antibody as a vaccine for high risk neuroblastoma. PROC ASCO 23:797 (Abst 8511) 2004.
120. Loh KC, Willert J, Meltzer W, Roberts W, Kerlin B, Kung F, Levy M, Kadota R, Yu A, Spear MA: Temozolomide (TMZ) and radiation (XRT) for aggressive pediatric CNS malignancies. PROC ASCO 23:811 (Abst 8566) 2004.
121. Yu AL, Batova B, Strother D, Angelini P, Castleberry R: Promising results of a pilot trial of GD₂ directed anti-idiotypic antibody as a vaccine for high risk neuroblastoma. Associazione

Italiana per la Lotta al Neuroblastoma, Advances in Neuroblastoma Research 2004 Conference 009.1, Page 75, 2004.

122. Yu J, Shao LE, Huang C-L, Yu AL: A murine model of human primary leukemia for studying leukemia-stromal interactions and prediction of clinical outcome. Blood 104(11):337a (abst 1192), 2004.
123. Diccianni MB, Pollock B, Devidas M, Yu AL: Hox11L2 expression and prognosis I T-cell lymphoblastic leukemia (T-ALL): A Children's Oncology Group Study. PROC AACR 46:1116 (abst 4729), 2005.
124. Chilcote R, Yu A, Diccianni MB: MTAP protein expression and its relationship with chemosensitivity in the NCI60 cell lines. PROC AACR 46:359 (abst 1532), 2005.
125. Li LH, Yu AL, Chen CH, Ho SF, Jiang KC, Wu JY, Chen YT: Genome-wide SNP scan detects submicroscopic chromosomal aberrations in acute lymphoblastic leukemia. 55th ASHG Annual Meeting 2005.
126. Chain P, Chen Y-Y, Lu P-J, Hsiao M, Yu A, Chen C-H: Novel Mass Spectrometry for Disease Diagnosis. 3rd Annual Congress of International Drug Discovery Science and Technology 2005.
127. Lin YC, Li LH, Yu AL, Diccianni MB, Wei CY, Chen CH, Ho SF, Jiang KC, Wu JY, Chen YT: Genome-wide SNP scan detects submicroscopic chromosomal aberrations in acute lymphoblastic leukemia. Joint 6th Human Genome Organization (HUGO) Pacific Meeting & 7th Asia-Pacific Human Genetics Conference (HUGO-AP 2006) 2006.
128. Lin YC, Diccianni MB, Lin HH, Lee CH, Lin RJ, Tsai MD, Yu AL: Human p16 γ , a novel transcriptional variant of p16^{INK4A}, co-expresses with p16^{INK4A} in cancer cells and is a potential cell cycle inhibitor PROC AACR 47:33, (abst LB-143), 2006.
129. Diccianni MB, Calin GA, Ferracin M, Liu CG, Negrini M, Croce CM, Yu AL: MicroRNA profiles of childhood T cell acute lymphoblastic leukemia PROC AACR 47:29, (abst 124), 2006.
130. Chang CH, Chou WC, Wang HC, Cheng CP, Chuang LC, Yeh TC, Hsieh YL, Ting HL, Yu AL, Shen CY, Wu PE: Breast cancer risk associated with genotype polymorphism of the genes involved in cell cycle G1/S regulation PROC AACR 47:1268, (abst 5399), 2006.
131. Kim Y, Yu AL, Diccianni MB. PIK3CA mutations are rare in neuroblastoma: development and use of a highly sensitive dHPLC assay for the mutational analysis of PIK3CA: PROC AACR 47:49, (abst 209), 2006.
132. Ling TY, Yu AL, Yu J: Identification of slow cycling, OCT-4+ stem/
133. progenitor cells from mouse lung tissues. The 4th ISSCR Annual Meeting, Toronto, Canada, June 29-July1, p. 108, 2006.

134. Elizabeth Nakae, John E. Cornell, George A. Calin, Brad H. Pollock, Carlo M. Croce, Alice Yu, Mitchell B. Diccianni(2007) MicroRNAs in T cell acute lymphoblastic leukemia. Proc. AACR 48:1071 (abst #4519)
135. Chang YJ, Huang JR, Tsai YC, Wu D, Fujio M, Wong CH, and Yu AL: Potent Immune-modulating and Anti-cancer Effects of NKT Stimulatory Glycolipid Analogs of α -GalactosylCeramide. Proc. AACR 48:1900 (abst).
136. Yu J, Ling TY, Chen, SH, Cheng MC, Lee SH, Wu TJ, Chien YL, Cho HC, Kuo MD, Yu AL: A Primitive Subpopulation of Pulmonary Cells Functions as Pulmonary Stem Cells and as Preferential Target for SARS and H5N1 Virus Infections. Proceeding of 5th ISSCR annual meeting, p. 59, 2007
137. Huang CC, Huang CW, Young HS, Lin JJ, YU AL, Yeh KT, Chen SN, Yu J: Dll4 is required for lymphatic vessel growth in zebrafish and is overexpressed in human lymphangioma. Proceedings of the 99th Annual Meeting of the AACR; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008 (abst #392).
138. Lin RJ, Lin YC, Kuso HH, Chen YY, Chang JCH, Chen J, Diccianni MB, London W, Yu AL: MicroRNA signature and expression of Dicer and Drosha can delineate clinical risk groups in neuroblastoma. Proceedings of the Joint Metastasis Research Society-AACR Conference on Metastasis, August 3-7, 2008 (abst).
139. Chang WW, Lee CH, Lee P, Lin J, Hsu CW, Yu J, Wong CH, Yu JC, Yu AL: Globo H expression is lower in breast cancer stem cells and its biosynthesis involves fucosyl transferases 1 and 2. Proceedings of the 99th Annual Meeting of the AACR; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008. (abst# 2026).